title: Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
authors.affiliation: Immunology Department, North Bristol NHS Trust, Bristol, United Kingdom. Electronic address: philip.bright@doctors.org.uk.
authors.forename: Philip D
authors.initials: PD
authors.lastname: Bright
authors.affiliation: Immunology Department, North Bristol NHS Trust, Bristol, United Kingdom.
authors.forename: Mark
authors.initials: M
authors.lastname: Gompels
authors.affiliation: Public Health Laboratory, Public Health England, Bristol, United Kingdom.
authors.forename: Matthew
authors.initials: M
authors.lastname: Donati
authors.affiliation: Immunology Department, North Bristol NHS Trust, Bristol, United Kingdom.
authors.forename: Sarah
authors.initials: S
authors.lastname: Johnston
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001769:Blood / Q000821:virology; D003587:Cytomegalovirus / Q000187:drug effects*; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D024882:Drug Resistance, Viral / Q000235:genetics*; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008297:Male; D008875:Middle Aged; D012263:Ribonucleosides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013183:Sputum / Q000821:virology; D013997:Time Factors; D004004:Dichlororibofuranosylbenzimidazole / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D015774:Ganciclovir; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D000077339:Leflunomide; D012263:Ribonucleosides; C400401:maribavir; D004004:Dichlororibofuranosylbenzimidazole
keywords: Cytomegalovirus treatment; Ganciclovir resistance; Maribavir; Primary immunodeficiency